Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
What it's best known for Helping people with a rare condition called EPP tolerate sunlight without pain, by building up pigment as a kind of protection
The launch of GLP-1 medications in 2021 signaled a major advancement in the treatment of obesity and weight-related issues
family history, physical inactivity, high-risk ethnicity, poor diet, hypertension, dyslipidemia, PCOS, prior gestational diabetes, prediabetes, or cardiovascular disease All adults aged 45 or older, regardless of weight Children aged 10 or older with overweight or obesity and two or more risk factors, screened at puberty onset Pregnant individuals: gestational diabetes screening at 2428 weeks New in ADA 2026 Screen individuals initiating immune checkpoint inhibitors, PI3K inhibitors, mTOR inhibitors, or high-dose glucocorticoids, a significant new addition for oncology and transplant patients
PMID: 30826183 Title: Distinct Modes of Presynaptic Inhibition of Cutaneous Afferents and Their Functions in Behavior Product/Service Type: Custom Antibody Production Service PNAS , 115(51): E12005-E12014
US$ 26.24
US$ 26.53
US$ 28.31
US$ 28.18
US$ 22.02
US$ 25.37
US$ 20.70
